Literature DB >> 32627843

Tildrakizumab in the treatment of moderate-to-severe hidradenitis suppurativa.

Yonatan Kok1, Jenny Nicolopoulos1, Anne Howard1, George Varigos1, Johannes Kern1, Con Dolianitis1.   

Abstract

Entities:  

Year:  2020        PMID： 32627843     DOI： 10.1111/ajd.13377

Source DB:  PubMed          Journal:  Australas J Dermatol        ISSN： 0004-8380            Impact factor:   2.875


× No keyword cloud information.
  3 in total

Review 1.  Paradoxical Hidradenitis Suppurativa during Biologic Therapy, an Emerging Challenge: A Systematic Review.

Authors:  Angelo Ruggiero; Fabrizio Martora; Vincenzo Picone; Laura Marano; Gabriella Fabbrocini; Claudio Marasca
Journal:  Biomedicines       Date:  2022-02-16

Review 2.  New and Emerging Targeted Therapies for Hidradenitis Suppurativa.

Authors:  Adela Markota Čagalj; Branka Marinović; Zrinka Bukvić Mokos
Journal:  Int J Mol Sci       Date:  2022-03-29       Impact factor: 5.923

3.  Recalcitrant Ulcerative Pyoderma Gangrenosum of the Leg Responsive to Tildrakizumab: A Case Report.

Authors:  Liang Joo Leow; Nicolas Zubrzycki
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-08-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.